Stockholm 12th of December 2024 - On stage of the 20th edition of the Dutch Life Sciences conference, Stijn Heessen, COO of Alder Therapeutics presented Alder’s mission to shape the future of regenerative medicine by developing an affordable ground-breaking replacement cell therapy for patients suffering from the blinding disease retinitis pigmentosa. Alder Therapeutics became the proud winner of the Investors Forum and was awarded a partnering ticket with a total value of €2,500 and a half-day Booster Session offered by PwC.
External link to article:
https://www.dutchlifesciences.com/news/article/121/alder-therapeutics-winner-investors-forum-2024
Alder Therapeutics is a virtual pre-clinical replacement cell therapy development company that is shaping the future of regenerative medicine. Founded in 2022 by seasoned cell therapy and industry experts, the company has two promising allogeneic stem cell therapy programs in the pipeline: one for degenerative eye diseases, and one for chronic heart disease. At the core of the company’s success is the AlderEdge™ platform — a novel approach to cell therapy development that keeps the commercial product in mind from the start for a de-risked route to success.
Kristian Tryggvason
CEO
Alder Therapeutics
kristian@aldertx.com
Want to support us on our journey to shape the future of regenerative medicine?
